Performance review: Tata India Consumer Fund
Performance review: Tata India Consumer Fund

Performance review: Tata India Consumer Fund

DSIJ Intelligence Article rating: 4.7

Tata India Consumer Fund is a thematic fund offering from Tata Mutual Fund. This fund follows the consumption theme. Read on to know more about its performance.

Nifty trend for Thursday
Nifty trend for Thursday

Nifty trend for Thursday

DSIJ Intelligence-3 Article rating: 4.7

If you are a trader and missed few glimpses of Wednesday’s trading session, then you would realise that you haven’t missed much as Nifty ended with a minuscule gain of 4.70 points or 0.04 per cent.

Rolls-Royce enters into strategic partnership with Infosys for aerospace engineering in India
Rolls-Royce enters into strategic partnership with Infosys for aerospace engineering in India

Rolls-Royce enters into strategic partnership with Infosys for aerospace engineering in India

DSIJ Intelligence Article rating: 4.6

Rolls-Royce, being one of the major world leaders in aerospace & defense technology, joined hands with the IT giant Infosys, which has deep knowledge in turbomachinery for sourcing engineering and R&D services for the civil aerospace business of Rolls-Royce.

Sensex recovers from days low; Adani Transmission jumps 11 per cent, Vakrangee locks in at upper circuit
Sensex recovers from days low; Adani Transmission jumps 11 per cent, Vakrangee locks in at upper circuit

Sensex recovers from days low; Adani Transmission jumps 11 per cent, Vakrangee locks in at upper circuit

DSIJ Intelligence Article rating: 4.3

Concluding today’s volatile trading session, Sensex recovered by 448 points from its today’s low of 44,169 levels to close at 44,618.04 levels down, by a mere 0.08 per cent or 37.40 points compared to its previous close. On the other hand, Nifty closed in green, up by 0.04 per cent or 4.70 points at 13,113.75 levels.

Alembic subsidiary gets USFDA nod to study oral DHODH inhibitor for SARS-CoV-2 infection
Alembic subsidiary gets USFDA nod to study oral DHODH inhibitor for SARS-CoV-2 infection

Alembic subsidiary gets USFDA nod to study oral DHODH inhibitor for SARS-CoV-2 infection

DSIJ Intelligence Article rating: 3.5

Rhizen Pharmaceuticals, a clinical-stage oncology-focussed biopharmaceutical company, and wholly-owned subsidiary of Alembic Pharma announced on Wednesday, the approval of its Investigational New Drug (IND) application by the US drug regulator, the United States Food and Drug Administration (USFDA) to study its oral DHODH inhibitor for SARS-CoV-2 infection.

Indian growth story continues with a surge in FPI, FDI & corporate bond market flows
Indian growth story continues with a surge in FPI, FDI & corporate bond market flows

Indian growth story continues with a surge in FPI, FDI & corporate bond market flows

Nidhi Jani Article rating: 4.6

Further, during Q2FY21, the total FDI inflows came in at USD 28,102 million. Out of which, equity inflows stood at USD 23,441 million or Rs 174,793 crore. With this, the total FDI equity inflow in FY21 stood at USD 30,004 million, 15 per cent greater than that of the corresponding period last year.

Five stocks with buying interest
Five stocks with buying interest

Five stocks with buying interest

DSIJ Intelligence Article rating: 4.2

The market opened in red on December 02, 2020, overall volumes in futures & options currently stand at 2,07,73,356 contracts with a turnover of Rs. 17,48,724.93 crore.

RSS
First26492650265126522654265626572658Last

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR